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Abstract
Nucleotide oligomerisation domain 2 (NOD2) is a component of the innate immunity known to be involved in the
homeostasis of Peyer patches (PPs) in mice. However, little is known about its role during gut infection in vivo. Yersinia
pseudotuberculosis is an enteropathogen causing gastroenteritis, adenolymphitis and septicaemia which is able to invade its
host through PPs. We investigated the role of Nod2 during Y. pseudotuberculosis infection. Death was delayed in Nod2
deleted and Crohn’s disease associated Nod2 mutated mice orogastrically inoculated with Y. pseudotuberculosis. In PPs, the
local immune response was characterized by a higher KC level and a more intense infiltration by neutrophils and
macrophages. The apoptotic and bacterial cell counts were decreased. Finally, Nod2 deleted mice had a lower systemic
bacterial dissemination and less damage of the haematopoeitic organs. This resistance phenotype was lost in case of
intraperitoneal infection. We concluded that Nod2 contributes to the susceptibility to Y. pseudotuberculosis in mice.
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Introduction
Caspase Recruitment Domain 15 (CARD15), which encodes
Nucleotide oligomerisation domain 2 (NOD2), is a member of the
phylogenetically conserved NACHT-leucine rich repeats (NLR)
gene family which is implicated in the innate immune response
[1]. Nod2 is an intracellular protein expressed in myelomonocytic
cells and activated epithelial cells [2–4]. In vitro, muramyl-
dipeptide (MDP) (a moiety of the bacterial cell wall peptidoglycane
(PGN) of almost all bacteria) has been identified as the minimal
bacterial motif recognized by NOD2 [5,6]. MDP activates NOD2,
leading to its interaction with the serine-threonine kinase RIP-like
interacting caspase-like apoptosis regulatory protein kinase (RICK)
and finally to the activation of the nuclear factor-kB (NF-kB)
pathway [5–7]. NOD2 mutations have been associated with
Crohn’s Disease (CD), a Human condition characterised by a
chronic or relapsing inflammation on the digestive tract (Hugot et
al. 2001; Ogura et al. 2001).
Only limited data are available about the role of Nod2 during
host pathogen interactions. In vitro, Nod2 has been found to be
involved in the bacterial clearance of Salmonella and Streptococcus
species [8]. In vivo, Nod2 deleted mice have been reported to be
more susceptible to oral infection with Listeria monocytogenes [9] and
this finding was paralleled to decreased secretion of some
antibacterial cryptidins by Paneth cells [9].
The genus of Yersinia includes three species that are pathogenic
for humans and rodents. Y. pestis is the causative agent of plaque.
Y. pseudotuberculosis and Y. enterocolitica are enteropathogens that
cause most often self limited enteritis and mesenteric adenolym-
phitis in Human. In some cases, especially in patients with
hemochromatosis, however, enteric Yersinia disseminates systemi-
cally with a case fatality of 70% [10]. In mice, oral inoculation
with enteropathogenic Yersinia results in translocation of bacteria
from the intestines to spleen and liver and subsequently in the
death of the animals [11].
Enteropathogenic Yersinia strains display a tropism to lymphoid
tissue [12]. The bacteria bind to and invade M cells within the
follicle-associated epithelium overlying the lymphoid follicles of the
Peyer’s patches (PPs) [13,14]. Following their entry into PPs, the
bacteria induce the host immune response, which is characterized
PLoS ONE | www.plosone.org 1 July 2008 | Volume 3 | Issue 7 | e2769by an inflammation with infiltration of neutrophils and macro-
phages [15].
We have previously shown that Nod2 is involved in the
homeostasis of PPs [16]. Nod2
2/2 mice are characterised by a
higher number of PPs and LFs after birth. In addition, PPs are
larger and contain an increased proportion of M cells and CD4
+
T-cells and higher levels of TNFa, IFNc, IL12 and IL4. In
contrast, little differences are found in the PP-free ileum and the
spleen of Nod2
2/2 mice. Finally, PP modifications are associated
with increased paracellular permeability and yeast/bacterial
translocation. The aim of this study is to further explore the role
of Nod2 in the function of PPs using a model of oral infection by Y.
pseudotuberculosis in a Nod2 invalidated mouse model.
Results
In order to determine if Nod2 plays a role in the immune
defence against Y. pseudotuberculosis we first established oral survival
curves and determined the oral lethal dose 50 (LD50) in Nod2
2/2
mice. Five groups of five Nod2
2/2 mice in the C57BL/6j genetic
background as well as the corresponding Nod2
+/+ control mice
were orogastrically inoculated with 10-fold serial dilutions of the Y.
pseudotuberculosis strain YPIII (pIB102) [17] (supplementary Figure
S1a). The Lethal Dose 50 (LD50) was only slightly higher for
Nod2 deficient mice than for wild type mice (1.4610
7 CFU versus
5.4610
6 CFU). Similar results were observed with knock-out and
wild type mice in the FVB/N genetic background with LD50
values respectively of 2.7610
6 CFU and 5.3610
5 CFU (supple-
mentary Figure S1b).
These limited differences in LD50 values did not argue for a
strong biological effect of Nod2 pathway in the host immune
response. However, it appeared that for all the tested doses, the
invalidated mice died later than the control mice in both the FVB/
N and C57BL/6j genetic backgrounds (supplementary Figure S1).
When comparing the Kaplan-Meyer curves using the Log-Rank
test, we found that this difference reached significance for some
inoculated doses (supplementary Figure S1) and for the pooled
data (p,0.01; Figure 1a,b).
Interestingly, it is to note that the slope of the survival curves
was similar in both Nod2
+/+ and Nod2
2/2 mice suggesting that,
even if delayed, the mechanisms of death (usually due to a
generalised infection) should be the same in both mouse strains. In
addition, the genetic susceptibility of FVBN mice is higher than
the C57BL/6 mice, confirming the importance of the genetic
background in Y. pseudotuberculosis infection.
In order to further confirm the role of Nod2 in the susceptibility
to Yersinia infection, we used an additional mouse model carrying
the mutation homologous to the CD associated frame-shift
mutation 1007fs (Nod2
mt/mt) [18]. Here too, after oral infection
with 1610
9 CFU of the YPIII(pIB102) strain, Nod2
mt/mt mice had
a survival advantage when compared to littermate wild type
controls (P,0.001; Figure 1c).
Further exploring the phenotype, we focused our work on
C57BL/6j mice orally inoculated with 1610
7 CFU of wild type Y.
pseudotuberculosis and sacrificed at the beginning of the fifth day
following infection, when all mice inoculated with this dose are still
alive. Nod2 deficient mice had lower bacterial counts, lower TNFa
Figure 1. Nod2 mediates susceptibility to Y. pseudotuberculosis infection in mice. Nod2
+/+ and Nod2
2/2 mice in the C57BL/6j and FVB/N
backgrounds were orogastrically inoculated with 10 fold dilutions ranging from 6,5610
5 to 6,5610
9 CFU of Y. pseudotuberculosis pIB102 wild-type
strain. Survival curves of mice, all different infection dose groups used for LD50 analysis confounded, are shown for the (a) C57BL/6j background and
(b) for the FVB/N background. Nod2
2/2 mice died significantly later than Nod2
+/+ control mice (p,0.01; Log-Rank test). (c) Nod2 mutated mice were
infected with 1610
9 CFU of YPIII(pIB102) and died significantly later than Nod2 wild type littermate controls (p,0.001; Log-Rank test). (d) No survival
difference was seen after intraperitoneal infection of Nod2
2/2 and Nod
+/+ mice with 5610
4 CFU of YPIII(pIB102) (P=0.61; Log-Rank test).
doi:10.1371/journal.pone.0002769.g001
Nod2 and Yersinia
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liver than wild type controls (P,0.01; Figure 2a–c). As a result, we
concluded that the better survival observed in Nod2
2/2 mice was
associated with a less intense systemic bacterial dissemination and
tissue damages in haematopoietic organs.
Because Nod2 is involved in the gut immune response, we tested
if the infection route influences the animal survival by infecting
Nod2
2/2 mice in the C57BL/6j background with 5610
4 CFU of
the YPIII(pIB102) strain via the intra-peritoneal route. In contrast
to oral infection, no differences were observed between Nod2
2/2
and control mice (Figure 2d). This finding was reproduced using
serial dilutions of the inoculum (data not shown). We thus
concluded that Nod2 mediates the susceptibility to infection with
Y. pseudotuberculosis via the oral but not the via the intra-peritoneal
route.
We thus hypothesized that the intestinal immune response
might be the key factor for the decreased systemic dissemination of
Y. pseudotuberculosis. In agreement with previous reports [15],
histological analysis of intestines showed that intestinal lesions were
mainly situated in areas containing lymphoid follicles and PPs
(data not shown). Consequently, we further focused on PP areas.
Five days after intragastric inoculation with Y. pseudotuberculosis,
Nod2
2/2 mice were characterized by lower bacterial counts in PPs
(P,0.05, Figure 3a) and the number of bacteria found in PPs was
correlated with the number of bacteria found in spleen and liver
(P,0.01). Furthermore, the decreased bacterial colonisation of PPs
was observed as early as day two after infection when little bacteria
have translocated into liver and spleens (p,0.05, supplementary
Figure S2). Taken together these results suggest that PP areas form
a more efficient barrier in infected Nod2
2/2 mice.
Figure 2. Lower bacterial counts and histological damage in organs of Nod2
2/2 mice (a–c) Nod2
2/2 and Nod2
+/+ mice in the C57BL/6j
background were orogastrically inoculated with 1610
7 CFU of YPIII(pIB102) and their livers and spleens were analyzed at day 5. (a) Bacterial counts
were lower in Nod2
2/2 (n=29) than in Nod2
+/+ (n=27) mice (Mann Whitney test, bars show medians). Detection limit was 10
2 CFU (b) TNFa levels in
spleen (ELISA) were lower in Nod2
2/2 (n=6) than in Nod
+/+ (n=5) mice (Student t-test) (c) Scores of histological damages were lower in Nod2
2/2
(n=18) than in Nod2
+/+ (n=15) mice (Student t-test). Photos show representative lesions in HE stained tissues. Arrows indicate lesions; double arrows
indicate the lesion shown in higher magnification. Error bars indicate mean+/2SEM. *P,0.05, **P,0.01.
doi:10.1371/journal.pone.0002769.g002
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translocation rate through PPs. No differences between Nod2
2/2
and Nod2
+/+ mice were found, neither in terms of bacterial flux
through PPs, nor in terms of bacterial colonisation of the tissue
after addition of 1610
7 CFU or 1610
8 CFU in the mucosal part
of the chamber (Figure 3b and data not shown). These findings
suggested that bacterial translocation through PPs was determined
by an active local immune response rather than by a passive
passage through the gut mucosa.
Consequently, we studied the cell composition of the PPs and
the bordering intestinal tissue. Under basal conditions, Nod2
2/2
and Nod2
+/+ mice showed no differences in the proportions of
CD3
+ T-cells, B220
+ B-cells and the number of macrophages and
neutrophils in the intestine (data not shown). In contrast, five days
after oral infection with Y. pseudotuberculosis, the Nod2
2/2 mice were
characterized by an increased inflammatory score in PPs and the
surrounding epithelium (P,0.01, Figure 3c). Indeed, Nod2
2/2
mice had often a marqued mucosal inflammation with punctuated
Figure 3. Nod2 modulates the local intestinal inflammatory response during Y. pseudotuberculosis infection. (a, c–d) Nod2
2/2 and
Nod
+/+mice were orogastrically inoculated with 1610
7 CFU of YPIII(pIB102) bacteria and sacrificed 5 days after inoculation. Their PP were removed
and analyzed. (a) Bacterial counts were significantly lower in Nod2
2/2 (n=29) than in Nod
+/+ (n=27) mice (Mann-Whitney-test) for a detection limit
(DL) of 10
2 cfu. (b) PPs from non infected mice were placed in a Ussing chamber and 1610
8 CFU/ml pIB102 were placed in the mucosal compartment
of the chamber. No differences between Nod2
2/2 (n=7) and Nod2
+/+ (n=7) mice for the bacterial translocation trough PP (mucosal to serosal flux,
P=0.85) as well as for the bacterial colonisation of the tissue (count of the bacteria remaining in the tissue after the experiment; P=0.94) were seen
at 120 min (Mann-Whitney test). Detection limit was 10
2 CFU. (c) Infiltration of macrophages and neutrophils was scored in PPs and their surrounding
epithelium. The infiltration score was higher in Nod2
2/2 (n=9) than in Nod2
+/+ (n=11) mice (Student t-test). Photos show representative MPO
staining of intestinal villi, crypts and PPs (d) KC concentrations were recorded by ELISA. KC level was higher in Nod2
2/2 (n=6) than in Nod2
+/+ (n=7)
mice (Student t-test). (e) Flow cytometry analyses revealed an increase of the relative proportion of CD3
+ T-cells after infection in Nod2
+/+ mice (n=6)
but not in Nod2
2/2 mice (n=6) (Student t-test). Error bars indicate mean+/2SEM. *P,0.05, **P,0.01, ***P,0.001.
doi:10.1371/journal.pone.0002769.g003
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+/+ mice had most often a mild
mucosal infiltrate without ulceration. This phenotype was
associated with an enhanced secretion of KC, an IL-8-homologue
implicated in neutrophil recruitment (P,0.05, Figure 3d). Nod2
2/
2 mice were also characterized by no change in the proportion of
CD3
+ T-cells in comparison to the basal (non infected) level, while
Nod2
+/+ mice showed an increased level of CD3
+ T-cells after
Yersinia infection (Figure 3e). No differences were found with
respect to B220
+ B-cells in both Nod2
+/+ and Nod2
2/2 mice (data
not shown).
Yersinia species are known to induce cell death [19]. We thus
explored this parameter in the Nod2
2/2 mice. Under basal
conditions, the number of dead cells in PPs and the surrounding
epithelial cells was low and there was no difference between
Nod2
2/2 and Nod2
+/+ mice (data not shown). In agreement with
the observation of a lower bacterial colonization of the gut mucosa
in Nod2
2/2 mice, we found fewer trypan blue and ethidium
homodimer-1 positive dead cells in PPs from these mice compared
to control mice (P,0.05; Figure 4a). In addition, Nod2
2/2 mice
showed significantly less cleaved caspase-3 positive epithelial cells
in the intestinal villi (P,0.01; Fig. 4b) and crypts (P,0.001;
Fig. 4b) surrounding PPs, suggesting that cell death induced by
Yersinia infection was at least in part related with apoptosis.
Finally, we explored the in vitro function of macrophages and
dendritic cells derived from bone marrow cells. We failed to
identify abnormalities in knock out mice for TNFa or IL1b
secretion, bacterial internalisation and cell survival after Y.
pseudotuberculosis infection (supplementary Figure S3).
Altogether, these data showed that the intestinal response of PPs
after oral infection with Y. pseudotuberculosis is impaired in Nod2
2/2
mice.
Discussion
Nod2 has been identified as an intracellular receptor of the
innate immune system. It is involved in the recognition of
pathogen associated molecular patterns present in the bacterial cell
wall but little is known about its role during the host response
Figure 4. Less apoptosis of epithelial cells surrouding PP areas in Nod2
2/2 mice Nod2
2/2 and Nod
+/+mice were orogastrically inoculated
with 1610
7 CFU of YPIII(pIB102) bacteria and sacrificed 5 days after inoculation. Their intestines were removed and analyzed.(a) Cell death measured
by the proportion of Trypan blue or Ethidium homodimer-1 positive cells was lower in the PPs of Nod2
2/2 mice (Student t-test). (b) Apoptosis
measured by the number of caspase-3 stained epithelial cells in the 100 intestinal villi and crypts surrounding PPs was also lower in Nod2
2/2 mice
(Student t-test). Photos show representative caspase-3 staining of intestinal villi and crypts. Error bars indicate mean+/2SEM. *P,0.05, **P,0.01,
***P,0.001.
doi:10.1371/journal.pone.0002769.g004
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contact with a non pathogenic bacterial flora Nod2
2/2 mice have
an increased number of PPs which are characterized by a large
proportion of CD4
+ T-cells and increased concentrations of pro-
inflammatory cytokines [16]. Here, we used Y. pseudotuberculosis as a
model to show that Nod2 also plays a role in the immune response
of PPs toward enteropathogenic bacteria.
We show that Nod2 is involved in the in vivo response towards Y.
pseudotuberculosis. This phenotype is not dramatic, as indicated by
the limited differences observed in the LD50 between knock out
and wild-type mice. However, this result is meaningful as indicated
by its reproducibility in several mouse models and in several
genetic backgrounds. Interestingly, the same phenotype is
observed in a knock out model and in a model of mice carrying
a mutation homologous to the main Human CD associated
mutation (1007 fs). This mutation is usually considered as a loss of
function mutation in Human while it has been associated with an
over stimulation of the IL-1b pathway in mouse [18]. It is out of
the scope of this paper to fully resolve the question but it is to note
that our results suggest that it is possible to conciliate the two
models at least in terms of the immune response to Y.
pseudotuberculosis.
For Y. pseudotuberculosis and Listeria monocytogenes [9], the
phenotype of Nod2 deficient mice is observed only when mice
are infected via the oral route. These observations suggest that
Nod2 has a special role in the intestine as also indicated by the
association between NOD2 mutations and CD. Indeed, the
intestinal phenotype of Nod2
2/2 mice is characterized by an
increased KC secretion and a stronger infiltration by macrophages
and neutrophils and finally by a lower bacterial count. In parallel
with the lower bacterial cell count, we found less apoptotic
damages in the mucosa and a limited bacterial dissemination
associated with a better survival.
If Nod2 is a susceptibility gene for Y. pseudotuberculosis, it also
mediates protection against Listeria monocytogenes [9]. In order to
know if the observed resistance toward Yersinia infection could be
seen with another enteropathogenic strain, we analysed the
survival curves after intragastric inoculation by 5610
8 CFU of
Salmonella typhimurium. In opposition to Y. pseudotuberculosis, Nod2
2/2
mice were found to be more sensitive to Salmonella infection
(P,0.05; Supplemenatry Figure S4). Furthermore, in vitro, Nod2
has been shown to participate in the bacterial clearance of
Salmonella [2] species and Streptococcus [8]. Thus, the negative role of
Nod2 observed after Yersinia infection appears to be the exception
rather than the rule.
Our data suggest that Y. pseudotuberculosis may interact with
Nod2 signalling pathways. The ability of Yersinia pseudotuberculosis to
multiply in PPs and to spread to deeper tissues is dependent on a
plasmid that is common to all Yersinia species [20]. This virulence
plasmid (pYV) encodes a type III secretion apparatus and several
secreted proteins called Yersinia outer proteins (Yops). Given the
intracellular localization of Nod2, the effector Yops seem to be
good candidates when searching for bacterial components able to
interact with Nod2 signalling. The Yop effectors have been shown
to interfere with several signal transduction pathways within
eukaryotic cells [21], paralyzing phagocytosis, cell migration, NF-
kB activation and other functions that are required for innate and
adaptive immune responses [22]. Further studies are now
necessary to identify how Y. pseudotuberculosis is able to interact
with Nod2 signalling.
Because NOD2 is a susceptibility gene for CD, the impact of
our observations for CD patients is questionable. Several lines of
evidence indicate that PPs may be important areas for the
occurrence of CD lesions. A spatial relationship between CD and
PPs is supported by the observation that CD lesions mainly occur
in areas rich in lymphoid follicles including the distal ileum and the
colon. In addition, Fujimura et al. have shown that the inaugural
CD lesions are centered by lymphoid follicles [23]. A temporal
relationship between CD and PPs has also been proposed
considering that ileal CD is rare in young and old people when
PPs are less developed [24–26]. Furthermore, we have previously
shown that Nod2 is involved in the homeostasis of PPs [16]. We
show now that Nod2 is also implicated in the PP immune response
towards Y. pseudotuberculosis and provide hereby further indirect
data in favour of a link between Nod2 and the function of PPs.
Additional studies are now needed to further study the role of
lymphoid tissues for the pathogenesis of CD.
It is also interesting to note that several data support a link
between Yersinia species and CD. First, the clinical presentation of
CD and Yersiniosis are both characterized by ileitis or ileocolitis
with granulomas and in some cases by reactive arthritis. Second,
many case reports and a case control study have shown that CD
may occur after a Yersiniosis [27]. Third, mononuclear cells from
mesenteric lymph nodes of CD patients are more reactive to Y.
enterocolitica when compared to other bacteria such as E.coli,
Salmonella agona, Candida albicans or Chlamydia trachomatis [28].
Fourth, Y. enterocolitica and Y. pseudotuberculosis have been found in
CD lesions [29–31]. Altogether, these data suggest further
exploring the relationship between the exposure to Yersinia and
the occurrence of CD.
Materials and Methods
Mice
Nod2
2/2 mice [16] and Nod2
mt/mt mice [18] have been
described previously. Nod2
2/2 mice were backcrossed at least 5
times with C57BL/6 or FVBN mice. Nod2
mt/mt mice were in a
mixed C57BL/66129 background. All mice as well as the
corresponding control mice were born, generated and housed at
the animal facility of Robert Debre ´ Hospital, Paris, France. 10–14
week old mice were used throughout the study. All mice were
housed in pathogen free conditions with free access to food and
water. Housing and experiments adhered to current institutional
animal healthcare guidelines and national legislation. All exper-
iments were approved by the local ethics committee.
Infection of mice
Bacterial strains used in this study were YPIII(pIB102) [17].
Bacteria from fresh selective agar plates were grown in LB over
night at 26uC and resuspended in PBS. For the LD50 analysis, 25
mice were inoculated intragastrically with 10 fold dilutions ranging
from 6,5610
5 to 6,5610
9 CFU using a gastric tube. Death was
recorded for 21days following inoculation and LD50 was
calculated using the Reed-Munch method [32]. 5610
4 CFU were
used for intraperitoneal infection and survival was recorded during
21 days. For survival experiments of Nod2
mt/mt mice, animals
were intragastrically inoculated with 1610
9 CFU. Salmonella enterica
serovar typhimurium (strain 22676) was a clinical isolate provided by
S.B. Salmonella were gown over night in LB medium at 37uC and
mice were incoluated with 100 ml of 1% bicarbonate and and
30 min later intragastrically infected with 56108 CFU.
For bacterial counts in organs and for ELISA assays, oral
infections were performed with 1610
7 CFU. At day 5, spleen, liver
and 3 PPs were removed from each mouse, washed thoroughly
and homogenised in PBS containing a complete protease inhibitor
cocktail (Roche). Serial dilutions were performed and plated on
selective LB-Agar. For ELISA assays, proteins were quantified by
protein assay (Biorad). ELISAs were performed in duplicates with
Nod2 and Yersinia
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instructions.
Histology and Immunohistochemistry
Spleens, livers and small intestines were fixed in 4% phosphate
buffered formalin and stained with haematoxylin and eosin.
Intestinal sections were scored for inflammatory infiltration of
neutrophils and macrophages and inflammatory lesions as
followed: 0: No lesion; 1: Mild mucosal inflammatory infiltrate
without ulceration; 2: Marked mucosal inflammation with
punctuate mucosal erosions, 3: Prominent inflammation with
ulceration extending through the muscularis mucosae. In liver and
spleen, inflammation was scored as followed: 0: no lesion; 1: rare
and small microabcesses. 2: frequent and/or large non confluent
lesions 3: confluent lesions with destruction of architecture.
Single-label immunohistochemistry was performed using ABC
kit (Vector laboratories). Briefly, 4 mm deparaffinised sections were
subjected to a heat-induced antigen recovery in sodium citrate
buffer solution pH6. Endogenous peroxidase was blocked with 3%
H2O2 (DAKO) and slides were incubated for 30 min with primary
antibodies to cleaved Caspase-3 (1/100, Asp 175, Cell Signaling
Technology), or Myeloperoxidase (Neo Markers). A biotin-labelled
secondary antibody was applied for 30 min, followed by avidin-
biotin-peroxidase conjugate for 30 min. For visualisation, perox-
idase enzyme substrate, 3,39-diaminobenzidine was added and
slides were counterstained with Harris haematoxylin. Positive cells
were evaluated in 100 intestinal villi and 100 crypts located on
each side of PP at high power magnification (640).
Flow cytometry analyses
PPs were removed, washed in PBS and cells were mechanically
extracted and passed through a mesh filter. Cells were then
centrifuged, washed in PBS and used for analysis. Staining was
performed using the following antibodies (PE-Cy5-anti-CD3
(17A2), PE-Cy7-anti-CD3 (145-2C11), PE-anti-CD45R/B220
(RA3-6B2), according to manufacturer’s protocols (BD Pharmin-
gen). Ethidium homodimer-1 staining was performed using a
commercially available kit (Molecular Probes). Data was acquired
on a dual laser FACScan flow cytometer (Becton Dickinson) and
analyzed using the Cell Quest 3.3 software (Becton Dickinson).
Cell populations were gated on the basis of forward and side
scatter to allow selection of the viable lymphocytes. Cells stained
with 0.04% Trypan blue dye were counted in a hemocytometer.
Ussing chamber experiments
Immediately after mouse sacrifice, a portion of jejunum
containing a PP was opened along the mesenteric border and
mounted in a 0.196 cm
2 Ussing chamber. Throughout the
experiment, tissues were maintained in circulating oxygenated
Ringer solution at 37uC and the electric resistance was monitored.
Bacteria (1610
8 CFU/ml) were added in the mucosal compart-
ment of the chamber. After 120 min, a sample was taken out from
the serosal side and the PP was removed, washed and
homogenized. Bacteria from the serosal side and the PP tissue
were counted on plated serial dilutions.
In vitro cell culture experiments
Bone marrow-derived dendritic cells (BMDC) were obtained as
previously described [33]. In brief, bone marrow was flushed from
the femurs and tibias of mice. White blood cells were plated in
IMDM medium (Biowhittaker) supplemented with 10% fetal calf
serum (FCS) (Gibco), 1% supernatant from the J558 cell line [34],
antibiotics (100 U of penicillin ml
21 and 100 mg of streptomycin
ml
21) and 5610
25 M 2-mercaptoethanol. On days 6 and 10,
loosely adherent cells were collected and replated in fresh medium.
Bone marrow-derived macrophages BMMP were prepared as
previously described [35]. Briefly, cells obtained from the bone
marrow were cultured for 5 to 6 days in DMEM medium
(Seromed, Berlin, Germany) supplemented with 10% FCS
(Dominique Dutscher, Brumath, France), 10% L-cell-conditioned
medium, 100 U of penicillin ml
21, and 100 mg of streptomycin
ml
21 at a concentration of 5610
5 cells ml
21.
Eighteen hours prior to infection, cells were washed with
DMEM medium without antibiotics and were incubated in
medium with 10% FCS and 5% L-cell-conditioned medium.
Bacteria from fresh selective agar plates were inoculated into 2 ml
LB medium with selection antibiotics and incubated over-night at
26uC with shaking. The number of bacteria was deduced of the
optical density measure at 600 nm. 10
8 bacteria were then added
into 2 ml of complete cell culture medium without antibiotics and
incubated 30 min at 26uC. After a temperature shift to 37uC,
bacteria were then added to cell cultures at a calculated MOI of 10
in 12 well plates. To facilitate bacterial adhesion to the cells, the
plates were centrifuged at 1300 rpm for 5 min. After 120 min,
gentamycin (30 mg/ml) was added in order to kill extra-cellular
bacteria. At 3 hours and 6 hours postinfection, the infected
macrophages were washed gently three times with PBS and lysed
by incubation in 0.5 ml of 0.1% Triton X-100 in PBS. After
incubation for 15 min at 37uC, the lysates were removed and the
wells were rinsed with 0.5 ml of PBS, and the lysates and rinses
from each well were pooled. The number of released viable
bacteria was determined by plating serial 10-fold dilutions on
selective LB agar. For cytokine analyses supernatants were
harvested 6 h after infection and cytokines were analyzes using
commercially available Elisa Assays (BD Bioscience) according to
manufacturer’s instructions. For counts of cell death, cells were
stained with 0.04% Trypan blue and counted in a hemocytometer.
Statistical analysis
Two group comparisons were performed using unpaired t-test
for data with Gaussian distribution and Mann-Whitney test if
distribution was not Gaussian. Survival times were analyzed using
Kaplan-Meyer curves and comparisons were performed using the
Log-Rank test. Statistical analysis was performed using GraphPad
Prism 4.00 (GraphPad Software, San Diego California USA) and
SAS 8.02 (SAS, Cary, N.C., USA) software packages for PC. A
value of P,0.05 was considered as statistically significant. All P
values are two sided.
Supporting Information
Figure S1 Survival curves of Nod2+/+ and Nod22/2 mice in
the C57BL/6j and FVB/N backgrounds following orogastrically
inoculation with 10 fold dilutions ranging from 6,56105 to
6,56109 CFU of Y. pseudotuberculosis YPIII(pIB102) strain
(n=5 Nod2+/+ and n=5 Nod22/2 bmice for each dose group).
Log-Rank test.
Found at: doi:10.1371/journal.pone.0002769.s001 (0.12 MB TIF)
Figure S2 Bacterial counts in PP and organs of Nod22/2 mice
(a–c) Nod22/2 (n=15) and Nod2+/+ (n=15) mice in the
C57BL/6j background were orogastrically inoculated with 16107
CFU of YPIII(pIB102) and bacterial counts in PPs, livers and
spleens were analyzed at day 2. Nod22/2 had lower bacterial
counts (P,0.05) in PPs than Nod2+/+ mice. No differences in
bacterial counts were found in liver or spleen. (Mann Whitney
test). Detection limit (DL) was 10
2 CFU.
Found at: doi:10.1371/journal.pone.0002769.s002 (0.09 MB TIF)
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PLoS ONE | www.plosone.org 7 July 2008 | Volume 3 | Issue 7 | e2769Figure S3 In vitro analyses of bone marrow derived macro-
phages and dendritic cells after Yersinia pseudotuberculosis
infection. (a–f) Macrophages and dendritic cells were derived
from bone marrow of Nod22/2 and Nod2+/+ mice. Cells were
left uninftected (0) or were infected with Y. pseudotuberculosis
YPIII(pIB102) (YP) at an MOI of 10. At 6 h post infection,
secretion of TNFa and IL-1b by macrophages (a, b) and dendritic
cells (c, d) of Nod22/2 cells did not differ from Nod2+/+ cells. (e)
No differences were found for tryptan blue positive macrophages.
(f) Gentamycine protection assays did not show differences of
intracellular surviving bacteria in macrophages 3 h and 6 h after
infection. (Student t-test). Data represent mean6SEM from three
independent experimens (triplicate).
Found at: doi:10.1371/journal.pone.0002769.s003 (0.11 MB TIF)
Figure S4 Nod22/2 mice are more susceptible to oral
Salmonella typhimurium infection. Nod22/2 (n=6) and
Nod2+/+ (n=6) mice in the C57BL/6j background were
orogastrically inoculated with 56108 CFU of S. typhimurium.
Survival was found to be altered in Nod22/2 mice (P,0.05; Log-
Rank test).
Found at: doi:10.1371/journal.pone.0002769.s004 (0.05 MB TIF)
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